SHANG.FOS.PHARM.GR.H YC 1 (08HH) — Cash Flow-to-Debt Ratio
SHANG.FOS.PHARM.GR.H YC 1 (08HH) has a Cash Flow-to-Debt Ratio of 0.09x as of December 2025, meaning its operating cash flow of €5.21 Billion could theoretically repay 0% of its total liabilities (€58.21 Billion) in one year. See how financially flexible is SHANG.FOS.PHARM.GR.H YC 1 to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
SHANG.FOS.PHARM.GR.H YC 1 Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for SHANG.FOS.PHARM.GR.H YC 1 across 5 annual periods. For the full cash flow conversion analysis, see SHANG.FOS.PHARM.GR.H YC 1 (08HH) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
Year-by-year debt coverage analysis for SHANG.FOS.PHARM.GR.H YC 1. Check 08HH cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | €5.21 Billion | €58.21 Billion | ▲ +15.1% |
| 2024 | 0.08x | €4.48 Billion | €57.53 Billion | ▲ +29.6% |
| 2023 | 0.06x | €3.41 Billion | €56.85 Billion | ▼ -24.5% |
| 2022 | 0.08x | €4.22 Billion | €53.05 Billion | ▼ -9.3% |
| 2021 | 0.09x | €3.94 Billion | €44.93 Billion | — |